FeaturedMedia Release
French doctors hail Race’s Bisantrene in new case report
Race Oncology is pleased to announce a case report describing the successful use of Bisantrene
Featured
Proactive Investor interviews John Cullity
Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the
Featured
New director upbeat about Race Oncology’s growth prospects
New Race non-executive director Dr John Cullity has used his first interview to highlight the
FeaturedMedia Release
Agreement signals new market opportunities for Race
Race Oncology has announced it has executed a global distribution agreement with UK-based,
FeaturedMedia Release
Race appoints former Sanofi executive to the Board
Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a
FeaturedMedia Release
Viralytics sale signals positive outlook for Race
In a major development for the Australian biotech sector, ASX-listed oncology drug developer,
FeaturedMedia Release
Race Oncology releases Investor Presentation
Race Oncology has released its Investor Presentation ahead of CEO Peter Molloy’s address
FeaturedMedia Release
Bisantrene Patent in US granted “Notice of Allowance”
A key Bisantrene patent has received “Notice of Allowance” in the United States,